{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:47:01Z","timestamp":1793191621288,"version":"4.5.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100019486","name":"Biocodex Microbiota Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019486","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s40120-024-00677-8","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T15:02:22Z","timestamp":1730732542000},"page":"27-43","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Use of Stiripentol in Patients with Dravet Syndrome: Common Practice Among Experts in Spain"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6292-3287","authenticated-orcid":false,"given":"Juan Jos\u00e9","family":"Garc\u00eda-Pe\u00f1as","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3322-4265","authenticated-orcid":false,"given":"Roc\u00edo","family":"Calvo-Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n","family":"Garc\u00eda-Ron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4515-0793","authenticated-orcid":false,"given":"Antonio","family":"Gil-Nagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2080-8042","authenticated-orcid":false,"given":"Vicente","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5058-0686","authenticated-orcid":false,"given":"Roc\u00edo","family":"S\u00e1nchez-Carpintero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,4]]},"reference":[{"issue":"Suppl 2","key":"677_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1469-8749.2011.03964.x","volume":"53","author":"C Dravet","year":"2011","unstructured":"Dravet C. Dravet syndrome history. Dev Med Child Neurol. 2011;53(Suppl 2):1\u20136. https:\/\/doi.org\/10.1111\/j.1469-8749.2011.03964.x.","journal-title":"Dev Med Child Neurol"},{"issue":"4","key":"677_CR2","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1002\/epi4.12832","volume":"8","author":"A Strzelczyk","year":"2023","unstructured":"Strzelczyk A, Lagae L, Wilmshurst JM, et al. Dravet syndrome: a systematic literature review of the illness burden. Epilepsia Open. 2023;8(4):1256\u201370. https:\/\/doi.org\/10.1002\/epi4.12832.","journal-title":"Epilepsia Open"},{"issue":"1","key":"677_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/epi4.12569","volume":"7","author":"E Cardenal-Munoz","year":"2022","unstructured":"Cardenal-Munoz E, Auvin S, Villanueva V, et al. Guidance on Dravet syndrome from infant to adult care: road map for treatment planning in Europe. Epilepsia Open. 2022;7(1):11\u201326. https:\/\/doi.org\/10.1002\/epi4.12569.","journal-title":"Epilepsia Open"},{"issue":"9","key":"677_CR4","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1111\/epi.17015","volume":"62","author":"W Li","year":"2021","unstructured":"Li W, Schneider AL, Scheffer IE. Defining Dravet syndrome: an essential pre-requisite for precision medicine trials. Epilepsia. 2021;62(9):2205\u201317. https:\/\/doi.org\/10.1111\/epi.17015.","journal-title":"Epilepsia"},{"issue":"6","key":"677_CR5","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1111\/epi.17239","volume":"63","author":"SM Zuberi","year":"2022","unstructured":"Zuberi SM, Wirrell E, Yozawitz E, et al. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022;63(6):1349\u201397. https:\/\/doi.org\/10.1111\/epi.17239.","journal-title":"Epilepsia"},{"issue":"Suppl 3","key":"677_CR6","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1017\/cjn.2016.243","volume":"43","author":"MB Connolly","year":"2016","unstructured":"Connolly MB. Dravet syndrome: diagnosis and long-term course. Can J Neurol Sci. 2016;43(Suppl 3):S3-8. https:\/\/doi.org\/10.1017\/cjn.2016.243.","journal-title":"Can J Neurol Sci"},{"key":"677_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.108661","volume":"130","author":"J Sullivan","year":"2022","unstructured":"Sullivan J, Deighton AM, Vila MC, et al. The clinical, economic, and humanistic burden of Dravet syndrome\u2014a systematic literature review. Epilepsy Behav. 2022;130: 108661. https:\/\/doi.org\/10.1016\/j.yebeh.2022.108661.","journal-title":"Epilepsy Behav"},{"key":"677_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.eplepsyres.2016.10.006","volume":"128","author":"MS Cooper","year":"2016","unstructured":"Cooper MS, McIntosh A, Crompton DE, et al. Mortality in Dravet syndrome. Epilepsy Res. 2016;128:43\u20137. https:\/\/doi.org\/10.1016\/j.eplepsyres.2016.10.006.","journal-title":"Epilepsy Res"},{"issue":"17","key":"677_CR9","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1212\/WNL.0000000000003685","volume":"88","author":"C Harden","year":"2017","unstructured":"Harden C, Tomson T, Gloss D, et al. Practice guideline summary: sudden unexpected death in epilepsy incidence rates and risk factors: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2017;88(17):1674\u201380. https:\/\/doi.org\/10.1212\/WNL.0000000000003685.","journal-title":"Neurology"},{"issue":"Suppl 2","key":"677_CR10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1528-1167.2011.03012.x","volume":"52","author":"JV Skluzacek","year":"2011","unstructured":"Skluzacek JV, Watts KP, Parsy O, Wical B, Camfield P. Dravet syndrome and parent associations: the IDEA League experience with comorbid conditions, mortality, management, adaptation, and grief. Epilepsia. 2011;52(Suppl 2):95\u2013101. https:\/\/doi.org\/10.1111\/j.1528-1167.2011.03012.x.","journal-title":"Epilepsia"},{"issue":"Suppl 2","key":"677_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1469-8749.2011.03965.x","volume":"53","author":"P De Jonghe","year":"2011","unstructured":"De Jonghe P. Molecular genetics of Dravet syndrome. Dev Med Child Neurol. 2011;53(Suppl 2):7\u201310. https:\/\/doi.org\/10.1111\/j.1469-8749.2011.03965.x.","journal-title":"Dev Med Child Neurol"},{"issue":"9","key":"677_CR12","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s40263-019-00666-8","volume":"33","author":"EC Wirrell","year":"2019","unstructured":"Wirrell EC, Nabbout R. Recent advances in the drug treatment of Dravet syndrome. CNS Drugs. 2019;33(9):867\u201381. https:\/\/doi.org\/10.1007\/s40263-019-00666-8.","journal-title":"CNS Drugs"},{"key":"677_CR13","unstructured":"European Medicines Agency. Diacomit (stiripentol): summary of product characteristics. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/diacomit-epar-product-information_en.pdf. Accessed 29 Apr 2024."},{"key":"677_CR14","unstructured":"United States Food and Drug Administration. Diacomit (stiripentol): prescribing information. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/206709s003,207223s003lbl.pdf. Accessed 29 Apr 2024."},{"issue":"4","key":"677_CR15","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s12325-024-02813-0","volume":"41","author":"A Bacq","year":"2024","unstructured":"Bacq A, Depaulis A, Castagne V, Le Guern ME, Wirrell EC, Verleye M. An update on stiripentol mechanisms of action: a narrative review. Adv Ther. 2024;41(4):1351\u201371. https:\/\/doi.org\/10.1007\/s12325-024-02813-0.","journal-title":"Adv Ther"},{"issue":"12","key":"677_CR16","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1111\/epi.12401","volume":"54","author":"S Auvin","year":"2013","unstructured":"Auvin S, Lecointe C, Dupuis N, et al. Stiripentol exhibits higher anticonvulsant properties in the immature than in the mature rat brain. Epilepsia. 2013;54(12):2082\u201390. https:\/\/doi.org\/10.1111\/epi.12401.","journal-title":"Epilepsia"},{"key":"677_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.13036","author":"N Specchio","year":"2024","unstructured":"Specchio N, Auvin S, Strzelczyk A, Brigo F, Villanueva V, Trinka E. Efficacy and safety of stiripentol in the prevention and cessation of status epilepticus: a systematic review. Epilepsia Open. 2024. https:\/\/doi.org\/10.1002\/epi4.13036. (accepted for publication).","journal-title":"Epilepsia Open"},{"issue":"9242","key":"677_CR18","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/s0140-6736(00)03157-3","volume":"356","author":"C Chiron","year":"2000","unstructured":"Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO Study Group. Lancet. 2000;356(9242):1638\u201342. https:\/\/doi.org\/10.1016\/s0140-6736(00)03157-3.","journal-title":"Lancet"},{"key":"677_CR19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1046\/j.1528-1157.2002.13802.x","volume":"43","author":"R Guerrini","year":"2002","unstructured":"Guerrini R, Tonnelier S, d\u2019Athis P, et al. Stiripentol in severe myoclonic epilepsy in infancy (SMEI): a placebo-controlled Italian trial [abstract# P496]. Epilepsia. 2002;43:155.","journal-title":"Epilepsia"},{"issue":"3","key":"677_CR20","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s40120-024-00623-8","volume":"13","author":"R Guerrini","year":"2024","unstructured":"Guerrini R, Chancharme L, Serraz B, Chiron C. Additional results from two randomized, placebo-controlled trials of stiripentol in Dravet syndrome highlight a rapid antiseizure efficacy with longer seizure-free periods. Neurol Ther. 2024;13(3):869\u201384. https:\/\/doi.org\/10.1007\/s40120-024-00623-8.","journal-title":"Neurol Ther"},{"issue":"4","key":"677_CR21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/14737175.2023.2195550","volume":"23","author":"A Vasquez","year":"2023","unstructured":"Vasquez A, Wirrell EC, Youssef PE. Stiripentol for the treatment of seizures associated with Dravet syndrome in patients 6 months and older and taking clobazam. Expert Rev Neurother. 2023;23(4):297\u2013309. https:\/\/doi.org\/10.1080\/14737175.2023.2195550.","journal-title":"Expert Rev Neurother"},{"issue":"12","key":"677_CR22","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1111\/dmcn.15638","volume":"65","author":"C Chiron","year":"2023","unstructured":"Chiron C, Chemaly N, Chancharme L, Nabbout R. Initiating stiripentol before 2 years of age in patients with Dravet syndrome is safe and beneficial against status epilepticus. Dev Med Child Neurol. 2023;65(12):1607\u201316. https:\/\/doi.org\/10.1111\/dmcn.15638.","journal-title":"Dev Med Child Neurol"},{"issue":"9","key":"677_CR23","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1111\/epi.14536","volume":"59","author":"C Chiron","year":"2018","unstructured":"Chiron C, Helias M, Kaminska A, et al. Do children with Dravet syndrome continue to benefit from stiripentol for long through adulthood? Epilepsia. 2018;59(9):1705\u201317. https:\/\/doi.org\/10.1111\/epi.14536.","journal-title":"Epilepsia"},{"issue":"6","key":"677_CR24","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/dmcn.13704","volume":"60","author":"KA Myers","year":"2018","unstructured":"Myers KA, Lightfoot P, Patil SG, Cross JH, Scheffer IE. Stiripentol efficacy and safety in Dravet syndrome: a 12-year observational study. Dev Med Child Neurol. 2018;60(6):574\u20138. https:\/\/doi.org\/10.1111\/dmcn.13704.","journal-title":"Dev Med Child Neurol"},{"issue":"11","key":"677_CR25","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1111\/epi.16363","volume":"60","author":"A Rosati","year":"2019","unstructured":"Rosati A, Boncristiano A, Doccini V, et al. Long-term efficacy of add-on stiripentol treatment in children, adolescents, and young adults with refractory epilepsies: a single center prospective observational study. Epilepsia. 2019;60(11):2255\u201362. https:\/\/doi.org\/10.1111\/epi.16363.","journal-title":"Epilepsia"},{"key":"677_CR26","unstructured":"Guerrini R, Serraz B, Chancharme L, Chiron C. Impact of stiripentol on seizure free days and new open label data from the STICLO clinical trials confirm its significant impact on seizure reduction and on quality of life in Dravet syndrome [abstract #2.444]. In: 35th International epilepsy congress, 2\u20136 September 2023. Dublin, Ireland."},{"issue":"11","key":"677_CR27","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1111\/j.1528-1167.2009.02179.x","volume":"50","author":"Y Inoue","year":"2009","unstructured":"Inoue Y, Ohtsuka Y, Oguni H, et al. Stiripentol open study in Japanese patients with Dravet syndrome. Epilepsia. 2009;50(11):2362\u20138. https:\/\/doi.org\/10.1111\/j.1528-1167.2009.02179.x.","journal-title":"Epilepsia"},{"key":"677_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109553","volume":"150","author":"C Ballesteros-Sayas","year":"2024","unstructured":"Ballesteros-Sayas C, Munoz-Montero A, Giorgi S, et al. Non-pharmacological therapeutic needs in people with Dravet syndrome. Epilepsy Behav. 2024;150: 109553. https:\/\/doi.org\/10.1016\/j.yebeh.2023.109553.","journal-title":"Epilepsy Behav"},{"key":"677_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2020.106535","volume":"170","author":"M Yamada","year":"2021","unstructured":"Yamada M, Suzuki K, Matsui D, Inoue Y, Ohtsuka Y. Long-term safety and effectiveness of stiripentol in patients with Dravet syndrome: interim report of a post-marketing surveillance study in Japan. Epilepsy Res. 2021;170: 106535. https:\/\/doi.org\/10.1016\/j.eplepsyres.2020.106535.","journal-title":"Epilepsy Res"},{"issue":"2","key":"677_CR30","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/epi4.12923","volume":"9","author":"R Guerrini","year":"2024","unstructured":"Guerrini R, Chiron C, Vandame D, Linley W, Toward T. Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: a network meta-analysis. Epilepsia Open. 2024;9(2):689\u2013703. https:\/\/doi.org\/10.1002\/epi4.12923.","journal-title":"Epilepsia Open"},{"key":"677_CR31","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.seizure.2024.02.004","volume":"117","author":"D Xia","year":"2024","unstructured":"Xia D, Zhang P, Chen Y, Liu X, Chen Y. Efficacy of pharmacological treatments for Dravet syndrome: systematic review and network meta-analysis. Seizure. 2024;117:90\u20137. https:\/\/doi.org\/10.1016\/j.seizure.2024.02.004.","journal-title":"Seizure"},{"issue":"7","key":"677_CR32","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1111\/epi.17274","volume":"63","author":"EC Wirrell","year":"2022","unstructured":"Wirrell EC, Hood V, Knupp KG, et al. International consensus on diagnosis and management of Dravet syndrome. Epilepsia. 2022;63(7):1761\u201377. https:\/\/doi.org\/10.1111\/epi.17274.","journal-title":"Epilepsia"},{"issue":"4","key":"677_CR33","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1124\/dmd.105.007237","volume":"34","author":"C Giraud","year":"2006","unstructured":"Giraud C, Treluyer JM, Rey E, et al. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab Dispos Biol Fate Chem. 2006;34(4):608\u201311. https:\/\/doi.org\/10.1124\/dmd.105.007237.","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"677_CR34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.eplepsyres.2016.12.014","volume":"130","author":"T Jogamoto","year":"2017","unstructured":"Jogamoto T, Yamamoto Y, Fukuda M, et al. Add-on stiripentol elevates serum valproate levels in patients with or without concomitant topiramate therapy. Epilepsy Res. 2017;130:7\u201312. https:\/\/doi.org\/10.1016\/j.eplepsyres.2016.12.014.","journal-title":"Epilepsy Res"},{"issue":"1","key":"677_CR35","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1124\/dmd.123.001511","volume":"52","author":"Y Masubuchi","year":"2024","unstructured":"Masubuchi Y, Takahashi C, Gendo R. Time-dependent inhibition of CYP1A2 by stiripentol and structurally related methylenedioxyphenyl compounds via metabolic intermediate complex formation. Drug Metab Dispos Biol Fate Chem. 2024;52(1):63\u20138. https:\/\/doi.org\/10.1124\/dmd.123.001511.","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"1","key":"677_CR36","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2174\/1570159X15666171109143654","volume":"17","author":"K Monostory","year":"2019","unstructured":"Monostory K, Nagy A, Toth K, et al. Relevance of CYP2C9 function in valproate therapy. Curr Neuropharmacol. 2019;17(1):99\u2013106. https:\/\/doi.org\/10.2174\/1570159X15666171109143654.","journal-title":"Curr Neuropharmacol"},{"issue":"5","key":"677_CR37","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/S0009-9236(97)90044-8","volume":"62","author":"A Tran","year":"1997","unstructured":"Tran A, Rey E, Pons G, et al. Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. Clin Pharmacol Ther. 1997;62(5):490\u2013504. https:\/\/doi.org\/10.1016\/S0009-9236(97)90044-8.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"677_CR38","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/epi.17162","volume":"63","author":"AS Schoonjans","year":"2022","unstructured":"Schoonjans AS, Roosens L, Dewals W, Paelinck BP, Ceulemans B. Therapeutic drug monitoring of fenfluramine in clinical practice: pharmacokinetic variability and impact of concomitant antiseizure medications. Epilepsia. 2022;63(3):686\u201396. https:\/\/doi.org\/10.1111\/epi.17162.","journal-title":"Epilepsia"},{"issue":"9","key":"677_CR39","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.braindev.2018.05.020","volume":"40","author":"A Alhakeem","year":"2018","unstructured":"Alhakeem A, Alshibani F, Tabarki B. Extending the use of stiripentol to SLC13A5-related epileptic encephalopathy. Brain Dev. 2018;40(9):827\u20139. https:\/\/doi.org\/10.1016\/j.braindev.2018.05.020.","journal-title":"Brain Dev"},{"key":"677_CR40","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.pediatrneurol.2022.11.017","volume":"139","author":"G Aungaroon","year":"2023","unstructured":"Aungaroon G, Mehta A, Horn PS, Franz DN. Stiripentol for drug-resistant epilepsy treatment in tuberous sclerosis complex. Pediatr Neurol. 2023;139:86\u201392. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2022.11.017.","journal-title":"Pediatr Neurol"},{"issue":"3","key":"677_CR41","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s40801-022-00305-7","volume":"9","author":"S Balestrini","year":"2022","unstructured":"Balestrini S, Doccini V, Boncristiano A, Lenge M, De Masi S, Guerrini R. Efficacy and safety of long-term treatment with stiripentol in children and adults with drug-resistant epilepsies: a retrospective cohort study of 196 patients. Drugs Real World Outcomes. 2022;9(3):451\u201361. https:\/\/doi.org\/10.1007\/s40801-022-00305-7.","journal-title":"Drugs Real World Outcomes"},{"key":"677_CR42","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.seizure.2021.04.012","volume":"88","author":"E Freri","year":"2021","unstructured":"Freri E, Castellotti B, Canafoglia L, et al. Severe epilepsy in CNTNAP2-related Pitt-Hopkins-like syndrome successfully treated with stiripentol. Seizure. 2021;88:143\u20135. https:\/\/doi.org\/10.1016\/j.seizure.2021.04.012.","journal-title":"Seizure"},{"issue":"1","key":"677_CR43","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/epi4.12847","volume":"9","author":"A Gil-Nagel","year":"2024","unstructured":"Gil-Nagel A, Aledo-Serrano A, Beltr\u00e1n-Corbellini \u00c1, et al. Efficacy and tolerability of add-on stiripentol in real-world clinical practice: an observational study in Dravet syndrome and non-Dravet developmental and epileptic encephalopathies. Epilepsia Open. 2024;9(1):164\u201375. https:\/\/doi.org\/10.1002\/epi4.12847.","journal-title":"Epilepsia Open"},{"key":"677_CR44","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.seizure.2021.03.019","volume":"88","author":"L Habermehl","year":"2021","unstructured":"Habermehl L, Mross PM, Krause K, et al. Stiripentol in the treatment of adults with focal epilepsy\u2014a retrospective analysis. Seizure. 2021;88:7\u201311. https:\/\/doi.org\/10.1016\/j.seizure.2021.03.019.","journal-title":"Seizure"},{"issue":"2","key":"677_CR45","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.braindev.2012.03.016","volume":"35","author":"D Merdariu","year":"2013","unstructured":"Merdariu D, Delano\u00eb C, Mahfoufi N, Bellavoine V, Auvin S. Malignant migrating partial seizures of infancy controlled by stiripentol and clonazepam. Brain Dev. 2013;35(2):177\u201380. https:\/\/doi.org\/10.1016\/j.braindev.2012.03.016.","journal-title":"Brain Dev"},{"issue":"11","key":"677_CR46","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1111\/j.1528-1157.1999.tb02048.x","volume":"40","author":"J Perez","year":"1999","unstructured":"Perez J, Chiron C, Musial C, et al. Stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia. 1999;40(11):1618\u201326. https:\/\/doi.org\/10.1111\/j.1528-1157.1999.tb02048.x.","journal-title":"Epilepsia"},{"issue":"6","key":"677_CR47","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/ane.12403","volume":"132","author":"A Strzelczyk","year":"2015","unstructured":"Strzelczyk A, Kortland LM, Knake S, Rosenow F. Stiripentol for the treatment of super-refractory status epilepticus. Acta Neurol Scand. 2015;132(6):435\u20139. https:\/\/doi.org\/10.1111\/ane.12403.","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"677_CR48","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ejpn.2014.11.008","volume":"19","author":"M Trivisano","year":"2015","unstructured":"Trivisano M, Specchio N, Vigevano F. Extending the use of stiripentol to other epileptic syndromes: a case of PCDH19-related epilepsy. Eur J Paediatr Neurol. 2015;19(2):248\u201350. https:\/\/doi.org\/10.1016\/j.ejpn.2014.11.008.","journal-title":"Eur J Paediatr Neurol"},{"key":"677_CR49","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jns.2016.12.020","volume":"373","author":"Y Uchida","year":"2017","unstructured":"Uchida Y, Kato D, Toyoda T, et al. Combination of ketogenic diet and stiripentol for super-refractory status epilepticus: a case report. J Neurol Sci. 2017;373:35\u20137. https:\/\/doi.org\/10.1016\/j.jns.2016.12.020.","journal-title":"J Neurol Sci"},{"issue":"4","key":"677_CR50","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/ane.12888","volume":"137","author":"Y Uchida","year":"2018","unstructured":"Uchida Y, Terada K, Madokoro Y, et al. Stiripentol for the treatment of super-refractory status epilepticus with cross-sensitivity. Acta Neurol Scand. 2018;137(4):432\u20137. https:\/\/doi.org\/10.1111\/ane.12888.","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"677_CR51","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/FTD.0b013e31825dc4a6","volume":"34","author":"TW May","year":"2012","unstructured":"May TW, Boor R, Mayer T, et al. Concentrations of stiripentol in children and adults with epilepsy: the influence of dose, age, and comedication. Ther Drug Monit. 2012;34(4):390\u20137. https:\/\/doi.org\/10.1097\/FTD.0b013e31825dc4a6.","journal-title":"Ther Drug Monit"},{"issue":"Suppl 6","key":"677_CR52","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/epi.12291","volume":"54","author":"DK Grosenbaugh","year":"2013","unstructured":"Grosenbaugh DK, Mott DD. Stiripentol in refractory status epilepticus. Epilepsia. 2013;54(Suppl 6):103\u20135. https:\/\/doi.org\/10.1111\/epi.12291.","journal-title":"Epilepsia"},{"issue":"Suppl 1","key":"677_CR53","first-page":"73","volume":"66","author":"A Strzelczyk","year":"2024","unstructured":"Strzelczyk A, Specchio N, Auvin S, Brigo F, Villanueva V, Trinka E. Efficacy of stiripentol in the management of status epilepticus [abstract no. P120]. Dev Med Child Neurol. 2024;66(Suppl 1):73.","journal-title":"Dev Med Child Neurol"},{"issue":"2","key":"677_CR54","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/jnr.23688","volume":"94","author":"M Verleye","year":"2016","unstructured":"Verleye M, Buttigieg D, Steinschneider R. Neuroprotective activity of stiripentol with a possible involvement of voltage-dependent calcium and sodium channels. J Neurosci Res. 2016;94(2):179\u201389. https:\/\/doi.org\/10.1002\/jnr.23688.","journal-title":"J Neurosci Res"},{"issue":"1","key":"677_CR55","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/0883073818811538","volume":"34","author":"EP Y\u0131ld\u0131z","year":"2019","unstructured":"Y\u0131ld\u0131z EP, Ozkan MU, Uzunhan TA, et al. Efficacy of stiripentol and the clinical outcome in Dravet syndrome. J Child Neurol. 2019;34(1):33\u20137. https:\/\/doi.org\/10.1177\/0883073818811538.","journal-title":"J Child Neurol"},{"key":"677_CR56","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.eplepsyres.2016.05.012","volume":"125","author":"P De Liso","year":"2016","unstructured":"De Liso P, Chemaly N, Laschet J, et al. Patients with Dravet syndrome in the era of stiripentol: a French cohort cross-sectional study. Epilepsy Res. 2016;125:42\u20136. https:\/\/doi.org\/10.1016\/j.eplepsyres.2016.05.012.","journal-title":"Epilepsy Res"},{"issue":"12","key":"677_CR57","doi-asserted-by":"publisher","first-page":"6395","DOI":"10.1007\/s00415-022-11304-7","volume":"269","author":"A Vakrinou","year":"2022","unstructured":"Vakrinou A, Murphy E, Sisodiya SM, Vivekananda U, Balestrini S. Risk factors and outcome of hyperammonaemia in people with epilepsy. J Neurol. 2022;269(12):6395\u2013405. https:\/\/doi.org\/10.1007\/s00415-022-11304-7.","journal-title":"J Neurol"},{"issue":"3","key":"677_CR58","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/JCP.0000000000001689","volume":"43","author":"YJ Wong","year":"2023","unstructured":"Wong YJ, Fan J, Wan A, Mihic T, Gnyra M. Valproic acid-associated hyperammonemia: a systematic review. J Clin Psychopharmacol. 2023;43(3):283\u201394. https:\/\/doi.org\/10.1097\/JCP.0000000000001689.","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"677_CR59","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/s0022-3476(82)80320-x","volume":"101","author":"Y Ohtani","year":"1982","unstructured":"Ohtani Y, Endo F, Matsuda I. Carnitine deficiency and hyperammonemia associated with valproic acid therapy. J Pediatr. 1982;101(5):782\u20135. https:\/\/doi.org\/10.1016\/s0022-3476(82)80320-x.","journal-title":"J Pediatr"},{"issue":"11","key":"677_CR60","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1177\/1060028019856008","volume":"53","author":"ML Buck","year":"2019","unstructured":"Buck ML, Goodkin HP. Stiripentol: a novel antiseizure medication for the management of Dravet syndrome. Ann Pharmacother. 2019;53(11):1136\u201344. https:\/\/doi.org\/10.1177\/1060028019856008.","journal-title":"Ann Pharmacother"},{"issue":"S01","key":"677_CR61","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.33588\/rn.73S01.2021250","volume":"73","author":"JJ Garcia-Penas","year":"2021","unstructured":"Garcia-Penas JJ, Gil Nagel-Rein A, Sanchez-Carpintero R, Villanueva-Haba V. Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts\u2019 recommendations for its use in clinical practice in Spain. Rev Neurol. 2021;73(S01):S1\u20138. https:\/\/doi.org\/10.33588\/rn.73S01.2021250.","journal-title":"Rev Neurol"},{"key":"677_CR62","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2147\/ppa.s10330","volume":"4","author":"M Airoldi","year":"2010","unstructured":"Airoldi M, Zaccarelli M, Bisi L, et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence. 2010;4:115\u201325. https:\/\/doi.org\/10.2147\/ppa.s10330.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"677_CR63","first-page":"32","volume":"100","author":"AD Halli-Tierney","year":"2019","unstructured":"Halli-Tierney AD, Scarbrough C, Carroll D. Polypharmacy: evaluating risks and deprescribing. Am Fam Physician. 2019;100(1):32\u20138.","journal-title":"Am Fam Physician"},{"key":"677_CR64","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1477-7525-2-58","volume":"2","author":"CA Marra","year":"2004","unstructured":"Marra CA, Marra F, Cox VC, Palepu A, Fitzgerald JM. Factors influencing quality of life in patients with active tuberculosis. Health Qual Life Outcomes. 2004;2:58. https:\/\/doi.org\/10.1186\/1477-7525-2-58.","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"677_CR65","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.yebeh.2011.04.060","volume":"21","author":"BM Li","year":"2011","unstructured":"Li BM, Liu XR, Yi YH, et al. Autism in Dravet syndrome: prevalence, features, and relationship to the clinical characteristics of epilepsy and mental retardation. Epilepsy Behav. 2011;21(3):291\u20135. https:\/\/doi.org\/10.1016\/j.yebeh.2011.04.060.","journal-title":"Epilepsy Behav"},{"key":"677_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109361","volume":"146","author":"CA Minderhoud","year":"2023","unstructured":"Minderhoud CA, Postma A, Jansen FE, et al. Gastrointestinal and eating problems in SCN1A-related seizure disorders. Epilepsy Behav. 2023;146: 109361. https:\/\/doi.org\/10.1016\/j.yebeh.2023.109361.","journal-title":"Epilepsy Behav"},{"issue":"4","key":"677_CR67","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.eplepsyres.2014.02.008","volume":"108","author":"Y Inoue","year":"2014","unstructured":"Inoue Y, Ohtsuka Y, Group STPS. Effectiveness of add-on stiripentol to clobazam and valproate in Japanese patients with Dravet syndrome: additional supportive evidence. Epilepsy Res. 2014;108(4):725\u201331. https:\/\/doi.org\/10.1016\/j.eplepsyres.2014.02.008.","journal-title":"Epilepsy Res"},{"issue":"2","key":"677_CR68","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.braindev.2014.04.003","volume":"37","author":"T Kouga","year":"2015","unstructured":"Kouga T, Shimbo H, Iai M, et al. Effect of CYP2C19 polymorphisms on stiripentol administration in Japanese cases of Dravet syndrome. Brain Dev. 2015;37(2):243\u20139. https:\/\/doi.org\/10.1016\/j.braindev.2014.04.003.","journal-title":"Brain Dev"},{"issue":"9","key":"677_CR69","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1111\/epi.12303","volume":"54","author":"EC Wirrell","year":"2013","unstructured":"Wirrell EC, Laux L, Franz DN, et al. Stiripentol in Dravet syndrome: results of a retrospective U.S. study. Epilepsia. 2013;54(9):1595\u2013604. https:\/\/doi.org\/10.1111\/epi.12303.","journal-title":"Epilepsia"},{"issue":"2","key":"677_CR70","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1017\/s0317167100030353","volume":"17","author":"RE Appleton","year":"1990","unstructured":"Appleton RE, Farrell K, Applegarth DA, Dimmick JE, Wong LT, Davidson AG. The high incidence of valproate hepatotoxicity in infants may relate to familial metabolic defects. Can J Neurol Sci. 1990;17(2):145\u20138. https:\/\/doi.org\/10.1017\/s0317167100030353.","journal-title":"Can J Neurol Sci"},{"issue":"11","key":"677_CR71","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1111\/epi.16684","volume":"61","author":"Q Zulfiqar Ali","year":"2020","unstructured":"Zulfiqar Ali Q, Marques P, Selvarajah A, Tabarestani S, Sadoway T, Andrade DM. Starting stiripentol in adults with Dravet syndrome? Watch for ammonia and carnitine. Epilepsia. 2020;61(11):2435\u201341. https:\/\/doi.org\/10.1111\/epi.16684.","journal-title":"Epilepsia"},{"key":"677_CR72","unstructured":"European Medicines Agency. Epidyolex (cannibidiol): summary of product characteristics. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/epidyolex-epar-product-information_en.pdf. Accessed 01 May 2024."},{"issue":"14","key":"677_CR73","doi-asserted-by":"publisher","first-page":"e1204","DOI":"10.1212\/wnl.0000000000005254","volume":"90","author":"O Devinsky","year":"2018","unstructured":"Devinsky O, Patel AD, Thiele EA, et al. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018;90(14):e1204\u201311. https:\/\/doi.org\/10.1212\/wnl.0000000000005254.","journal-title":"Neurology"},{"key":"677_CR74","unstructured":"European Medicines Agency. Fintelpa (fenfluramine): summary of product characteristics. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fintepla-epar-product-information_en.pdf. Accessed 01 May 2024."},{"issue":"3","key":"677_CR75","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1517\/14740330902931524","volume":"8","author":"RB Rothman","year":"2009","unstructured":"Rothman RB, Baumann MH. Serotonergic drugs and valvular heart disease. Expert Opin Drug Saf. 2009;8(3):317\u201329. https:\/\/doi.org\/10.1517\/14740330902931524.","journal-title":"Expert Opin Drug Saf"},{"key":"677_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2020.106367","volume":"164","author":"N Trabs","year":"2020","unstructured":"Trabs N, Trabs M, Stodieck S, House PM. Influence of stiripentol on perampanel serum levels. Epilepsy Res. 2020;164: 106367. https:\/\/doi.org\/10.1016\/j.eplepsyres.2020.106367.","journal-title":"Epilepsy Res"},{"key":"677_CR77","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.pediatrneurol.2020.01.005","volume":"107","author":"JW Wheless","year":"2020","unstructured":"Wheless JW, Fulton SP, Mudigoudar BD. Dravet syndrome: a review of current management. Pediatr Neurol. 2020;107:28\u201340. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2020.01.005.","journal-title":"Pediatr Neurol"},{"key":"677_CR78","unstructured":"Dinsmore S. Center for Drug Evaluation and Research: Diacomit (stiripentol) clinical review. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/206709Orig1s000,207223Orig1s000MedR.pdf. Accessed 01 May 2024."},{"key":"677_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.993906","volume":"13","author":"LM Clayton","year":"2022","unstructured":"Clayton LM, Williams E, Balestrini S, Sisodiya SM. Case report: Dravet syndrome, feeding difficulties and gastrostomy. Front Neurol. 2022;13: 993906. https:\/\/doi.org\/10.3389\/fneur.2022.993906.","journal-title":"Front Neurol"},{"issue":"1","key":"677_CR80","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/ane.12611","volume":"135","author":"S Balestrini","year":"2017","unstructured":"Balestrini S, Sisodiya SM. Audit of use of stiripentol in adults with Dravet syndrome. Acta Neurol Scand. 2017;135(1):73\u20139. https:\/\/doi.org\/10.1111\/ane.12611.","journal-title":"Acta Neurol Scand"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00677-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-024-00677-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00677-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T16:18:24Z","timestamp":1737821904000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-024-00677-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,4]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["677"],"URL":"https:\/\/doi.org\/10.1007\/s40120-024-00677-8","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,4]]},"assertion":[{"value":"10 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Juan Jos\u00e9 Garc\u00eda-Pe\u00f1as has participated in advisory boards and symposia organized by Bial, Biocodex, Eisai Inc, Jazz Pharmaceuticals, Nutricia, Sanofi, and UCB; and has received congress sponsorship from Bial, Eisai Inc, Jazz Pharmaceuticals, Nutricia, Sanofi, and UCB. Roc\u00edo Calvo-Medina has participated in advisory boards and symposia organized by Biocodex. Adri\u00e1n Garc\u00eda-Ron has participated in advisory boards and symposia organized by Biocodex, Eisai Inc, Jazz Pharmaceuticals, and UCB. Antonio Gil-Nagel has participated in advisory boards and symposia organized by Angelini Pharma, Bial, Biocodex, Eisai, Jazz Pharmaceuticals, Rapport Therapeutics, Stoke, and UCB. Vicente Villanueva has participated in advisory boards and symposium organized by Angelini Pharma, Bial, Biocodex, Eisai Inc, Jazz Pharmaceuticals, Novartis, Paladin, Takeda, UCB, and Xenon. Roc\u00edo S\u00e1nchez-Carpintero has participated in advisory boards and symposium organized by Biocodex, Jazz Pharmaceuticals, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}